Staar Surgical Co. Aktie
42,80 €
Deine Einschätzung
Staar Surgical Co. Aktie
Was spricht für und gegen Staar Surgical Co. in den nächsten Jahren?
Pro
Kontra
Rendite von Staar Surgical Co. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Staar Surgical Co. | -4,21 % | 1,85 % | 30,80 % | -30,49 % | 53,91 % | -59,62 % | - |
Orasure Tech | 2,41 % | 2,05 % | -14,14 % | -22,79 % | -33,15 % | -38,41 % | -40,62 % |
scPharmaceuticals | 2,83 % | 1,44 % | -13,11 % | -51,82 % | -26,26 % | -22,91 % | - |
SI-BONE Inc | -2,78 % | 1,41 % | 2,13 % | -27,64 % | -24,21 % | -49,65 % | - |
Kommentare
News
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, comes to
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today